Author Archives: Dan Stanton

Pall and Cytiva reaping $1bn coronavirus bonus for Danaher

Danaher Corporation says its bioprocessing businesses Pall Biotech and Cytiva have secured over $1 billion in COVID-19 related orders and expects further windfalls as vaccines and therapies reach approval. When the coronavirus pandemic emerged earlier this year, commentators noted the financial opportunity for bioprocess vendors in supporting industry’s efforts in developing and commercializing vaccines, therapeutics, and diagnostics. As the year progresses, these opportunities are materializing in quarterly statements, with Danaher Corporation the latest company showing a COVID-19 tailwind across its…

Thermo Fisher: ‘$700m COVID CapEx easily repurposed post-pandemic’

An additional $700 million capacity buildout to meet COVID-related demand will serve the longer-term non-pandemic-related biopharma market, says Thermo Fisher An unprecedented third quarter saw Thermo Fisher report a 36% rise in revenues year-on-year to $8.52 billion across all its segments. Its Life Sciences Solutions Segment – which includes its biosciences and bioproduction business units – saw a 101% rise to $3.42 billion, while its Laboratory Products and Services Segment – which includes drug manufacturing – increased by 19% to…

Swiss plant demonstrates synergies of KBI and Selexis acquisitions for JSR

A facility in Geneva will be home to two of JSR Life Sciences acquisitions offering customers both cell line development and drug substance manufacturing. Financial details of the new facility, occupying 8,700 square meters in the Stellar 32 campus in Geneva, Switzerland, have not been divulged, but will house both biologics manufacturer KBI Biopharma and cell line developer Selexis. Both companies are owned by JSR Life Sciences, a California-headquartered firm which has been upping its presence in the bioprocess space…

Filling up: Thermo Fisher plans $130m Singapore plant

Thermo Fisher will add two filling lines in Singapore to support growing demand for sterile injectables. The $130 million facility will be established with the support of the Singapore Economic Development Board (EDB) and operated by Thermo Fisher. “Thermo Fisher will be building out and operating a new facility that will serve as a new regional steriles manufacturing site for our customers and, in addition, will provide priority access to the Singapore government during future health emergencies,” a Thermo Fisher…

With $30m in hand, Ori looks to advance closed cell therapy tech

Ori Biotech will use $30 million from a Series A financing round to finalize and test its closed and automated cell and gene therapy technology. In January, Ori Biotech came out of stealth mode through a $9.4 million seed round, introducing the cell and gene therapy space to its technology platform, which aims to significantly reduce the cost of production of such therapies. Nine months on and the firm has raised a further $30 million in a Series A financing…

CDMO selection ‘the last barrier’ to ADC advancement

The complex and multiple parts of antibody-drug conjugate (ADC) manufacture means it is integral to choose a CDMO with mAb, small molecule, and bioconjugation expertise, say WuXi Biologics and WuXi STA. The onslaught of ADCs is a hardy perennial in the pages of this publication and others when it comes to predicting the future of medicine. In 2011 when Adcetris (brentuximab vedotin) – then only the second ADC – was approved, it was predicted to be the watershed moment and…

J&J trial pause does not bode well for viral-vector COVID vaccines, analyst

Johnson & Johnson says the pausing of dosing in trials of its COVID-19 candidate is not unusual, but one analyst believes this could have significant negative impact for viral-vector based vaccines. Johnson & Johnson announced at the beginning of the week it has temporarily paused further dosing in all its COVID-19 vaccine candidate clinical trials due to an unexplained illness in a study participant. This included the Phase III ENSEMBLE trial of JNJ-78436735, also known as Ad26.COV2-S, recombinant, which is…

Lusk for life: Abzena $60m plant to support Ph III and commercial biologics

Abzena has begun operations at its 50,000 square-foot ‘Lusk’ facility boasting single-use bioreactors up to 2,000 L to support late-stage and commercial biologics. Contract development and manufacturing organization (CDMO) Abzena has further expanded its biologics offering, opening a $60 million facility in San Diego, California. The site houses a process development laboratory, two cGMP manufacturing cleanrooms for 500 L and 2,000 L scale bioreactors, a GMP warehouse, and analytical development and quality control (QC) laboratories. “We are already operational and…

Pfizer/BioNTech recruits Rentschler to support COVID-19 vaccine

CDMO Rentschler will be responsible for downstream processing of batches of Pfizer/BioNTech’s COVID-19 vaccine candidate BNT162b2 from its site in Laupheim, Germany. BNT162b2 is one of the frontrunners in the race to develop a vaccine against COVID-19. The Phase III candidate is based on messenger RNA (mRNA) and being produced at several facilities in Germany run by developer BioNTech. But now BioNTech and its partner Pfizer have selected contract development and manufacturing organization (CDMO) Rentschler to support production as it…

Navigo and Repligen team on COVID-19 vaccine affinity resin

Protein A-derived affinity ligands against the COVID-19 spike protein coupled to chromatography beads can resolve purification challenges in the development of coronavirus vaccines, say Navigo and Repligen. Bringing a vaccine against COVID-19 to market involves numerous challenges, not least on the manufacturing side. In downstream processing (DSP), the speed of purification and the yield of the purified product are key to ensuring supply of a quality vaccine. As such, bioprocess technology firm Repligen teamed with protein engineering firm Navigo Proteins…